Besides its utility for HCC screening, serum DCP can also be used as a clinicopathologic or prognostic indicator for HCC patients and potentially to be more helpful than AFP in reflecting the aggressive invasive distinctiveness of HCC. This evidence concerns the gene AFP and hepatocellular carcinoma.